- Primary endpoint of QUILT-3.078 is overall survival; median overall survival has not yet been reached, with 19 of 23 enrolled patients alive as of January 22, 2026
- Fourteen patients have evaluable data, with the longest survival from time of disease recurrence reaching 12 months to date and ongoing
- Baseline mean absolute lymphocyte count (ALC) among these 14 patients was 0.9 x 103/uL, confirming severe lymphopenia at enrollment
- ALC increased within one treatment cycle, with mean ALC rising to ≥ 1.4 x 103/uL (p
ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA® Plus CAR-NK, Chemo-Free Therapy
Key figures
- Baseline mean absolute lymphocyte count (ALC) among these 14 patients was 0.9 x 103/uL, confirming severe lymphopenia at enrollment
- ALC increased within one treatment cycle, with mean ALC rising to ≥ 1.4 x 103/uL (p
On 6ix: 6ix.com/news/immunitybio-reports-median-overall-survival-not-yet-reached-and-lymphopenia-reversed
Earlier from ImmunityBio
- ImmunityBio Advances Regulatory Discussions with FDA on Potential Resubmission Path for ANKTIVA® in BCG-Unresponsive Papillary Bladder Cancer
- ImmunityBio Announces Durable Complete Response of 15 Months with a Chemotherapy-Free CD19 CAR-NK Cell Therapy in Waldenstrom Lymphoma
- ImmunityBio Advances First-Line BCG Naive NMIBC Program with Enrollment Exceeding Expectations and Positive Interim Analysis for ANKTIVA® Plus BCG
- ImmunityBio Reports Continued Execution and Sales Momentum With $113 Million of Preliminary Net Product Revenue—a 700% increase year-over-year
- Saudi FDA Grants Accelerated Approval to ImmunityBio’s ANKTIVA® In Combination with Checkpoint Inhibitors for Metastatic Non-Small Cell Lung Cancer
Later from ImmunityBio
- ImmunityBio Launches Phase 2 Chemotherapy-Free CAR-NK Cell Therapy Trial with ANKTIVA® (ResQ215B) in Indolent Lymphomas
- ImmunityBio Reports Productive Regulatory Engagement with Saudi Food and Drug Authority at USA-Saudi Biotech Alliance Meeting Hosted by the Ministry of Investment of Saudi Arabia
- ImmunityBio Receives Authorization from the European Commission for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ, Expanding Global Access to 33 Countries
- ImmunityBio Expands Access to ANKTIVA® in EU with New Distribution Partnership and Opens Irish Subsidiary to Support European Launch
- ImmunityBio Partners with Biopharma and Cigalah Healthcare to Launch ANKTIVA® in Saudi Arabia for Bladder and Lung Cancer Patients
Follow ImmunityBio into a list and get an email when it puts out news.
Follow ImmunityBio